

Pfizer's commitment to genitourinary (GU) cancer medicine.

Powered by experience.
Led by science.
Driven by patient care.

GU cancers are pervasive and difficult to treat.

In the U.S., GU tumors make up

1/4

of all solid tumors

GU tumors make up

23%

of all cancer diagnoses in the U.S.

GU cancers make up

11%

of all cancer deaths in the U.S.

U.S. Data. Estimated new cases are based on 2004-2018 incidence data as reported by the North American Association of Central Cancer registries. Estimated deaths are based on 2005-2019 US mortality data as reported by the National Center for Health Statistics, Centers for Disease Control and Prevention.



Pfizer Oncology is a leader with deep expertise in helping people with GU cancers.

At the heart of our R&D efforts are our colleagues who have developed a deep understanding of the science underlying this complex and heterogeneous group of cancers.

Driven by our desire to help patients, we are following the science by:

- Exploring treatment combinations
- Forming strategic partnerships within the GU community
- Investing in R&D to support a pipeline of compounds



Committed to equitable care for everyone with GU cancers

Complex barriers prevent some people with GU cancers from getting appropriate care for their disease.

Disparities in care lead to greater disparities in patient outcomes.

Equity is at the center of all we do

Pfizer is working closely with the GU community to understand barriers to GU cancer care.

- Collaborating with partners to understand patients' needs
- Developing initiatives to support the GU community
- Improving diversity in clinical trials

